• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

DTx Pharma completes $100M Series B

March 1, 2021 By Sean Whooley

RNA-based therapeutic developer DTx Pharma announced today that it completed a $100 million Series B financing round.

RA Capital Management led the financing round with participation from new investors Access Biotechnology, Surveyor Capital (a Citadel company), Cormorant Asset Management, Janus Henderson Investors, and Logos Capital.

Additionally, existing investors Friedman Bioventure Fund, Eli Lilly, Viva BioInnovator and ExSight Ventures participated, according to a news release. In connection with the financing, RA Capital Management principal Matthew Hammond and Access Biotechnology partner Dr. Dan Becker will join DTx Pharma’s board of directors.

Proceeds from the financing are earmarked for advancing DTx Pharma’s Falcon (fatty acid ligand conjugated oligonucleotide) platform technology as it looks to treat ocular, neuromuscular and CNS diseases.

The Falcon delivery platform is designed to utilize fatty acids as targeting ligands to enable cellular uptake and promote the biodistribution of RNA therapeutics.

“The DTx Pharma team has uncovered new ways to leverage fatty acids to overcome some of the challenges that have greatly limited RNA therapeutics as a class,” DTx Pharma CEO Arthur T. Suckow said in the release. “These funds will allow us to utilize our FALCON fatty acid motifs to advance assets into clinical development across several therapeutic areas over the next few years.”

Filed Under: Business/Financial News, Food & Drug Administration (FDA), Funding Roundup, Neurological, Optical/Ophthalmic, Pharmaceuticals Tagged With: DTx Pharma

IN CASE YOU MISSED IT

  • Medtronic to invest $50M in India Diabetes center
  • Flat Medical partners with Mercury Medical on smart syringe distribution
  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS